- Most Recent Funding
- $22.7 Million Private Equity on February 12, 2014
Nuron Biotech Inc. develops specialty biologics and vaccines. Its product pipeline comprises central nervous system products, such as NU100, a recombinant human interferon beta-1b for the treatment of relapsing remitting multiple sclerosis; wound healing products, including NU200, a recombinant human epidermal growth factor product for healing diabetic foot ulcers and burns; and HibTITER, a conjugate vaccine. The company was founded in 2010 and is based in Exton, Pennsylvania.
Current Team (4)Update
Funding Rounds (2) - $52.7MUpdate
1 East Uwchlan Avenue
Exton, PA 19341